Cervical cancer is a leading cause of morbidity and mortality among women worldwide, especially in the developing countries ([@bib19]; [@bib21]). Infection with oncogenic types of human papillomavirus (HPV) is an important factor in the development of cervical cancer ([@bib24]; [@bib35]). The persistent HPV infection induces an inflammatory response. Inflammation is an important component in the majority of tumour types. The outcome of this inflammatory response surrounding the cancer cells is dependent on the composition of the inflammatory infiltrate and locally produced signalling molecules ([@bib6]). Although inflammatory cells within the neoplastic lesion are capable of generating an anti-tumour response, this does not efficiently occur ([@bib10]; [@bib18]).

Inflammatory cells are attracted to the tumour site by locally produced cytokines and chemokines ([@bib2]; [@bib34]). Cervical cancer cells are known to produce an extensive range of cytokines and chemokines, such as CCL2, GM-CSF, TNF*α* and interleukin (IL)-12 ([@bib5]; [@bib11]; [@bib41]). In addition to attracting inflammatory cells, these cytokines and chemokines influence the activation status and function of infiltrating antigen-presenting cells and stromal cells, thus influencing the course of the disease ([@bib15]; [@bib2]).

In a previous study, we have shown that high expression levels or undetectable levels of *IL-12p40* mRNA in cervical carcinoma are associated with an improved overall survival compared with low amounts of *IL-12p40* that were associated with poor survival ([@bib42]). As IL-12 is known to stimulate effector cell populations, such as cytotoxic T cells and natural killer cells ([@bib28]; [@bib32]), our results suggest a dual role for *IL-12p40.*

The IL-12 cytokine family includes IL-12, IL-23, IL-27 and IL-35 ([@bib38]). From this family, IL-12 and IL-23 share the IL-12p40 subchain. Interleukin-12 is composed of IL-12p40 and IL-12p35, whereas IL-23 is composed of IL-12p40 and IL-23p19. Interleukin-23 has, amongst others, an important role in the IL-17/IL-23 pathway, resulting in the maintenance and expansion of Th17 cells ([@bib14]). In addition to IL-23, IL-1 and IL-6 are thought to have an important role in the induction of Th17 cells in humans ([@bib1]). The effect of IL-23 on cancer progression or cancer eradication is still not clear ([@bib16]; [@bib26]).

To further delineate the role of IL-12p40 in cervical carcinoma, we have quantified the mRNA expression levels of *IL-23p19*, and compared its expression level with *IL-12p35* and *IL-12p40* to investigate the relative importance of IL-12 and IL-23 in the tumour microenvironment. In addition, we have investigated the role of IL-1 and IL-6 in the tumour microenvironment by determining both the number of IL-1-positive cells and the number of IL-6-positive cells. Finally, we have assessed the association between *IL-23p19*, *IL-12p35*, *IL-12p40,* high number of IL-6-positive cells and clinicopathological parameters.

Material and methods
====================

Patient material
----------------

Between 1985 and 1995, 254 untreated patients suffering from primary cervical carcinoma with stage IB and IIA underwent a radical hysterectomy type III with lymphadenectomy. From the tissue obtained, based on the availability of the material, 90 tissue samples were accessible for research. Tissues were routinely embedded in paraffin after 10% formalin fixation. The tissue samples of each patient were examined by a pathologist for the presence of tumour. Tumour percentage varied between 20% and 90%, with median 60%. The characteristics of the patients are depicted in [Table 1](#tbl1){ref-type="table"}. Forty-seven patients received post-operative radiotherapy because of either tumour-positive lymph nodes or the presence of positive risk factors described by the Sedlis criteria ([@bib25]; a combination of two of the following unfavourable prognostic parameters: depth of infiltration ⩾15 mm (deep stromal invasion; middle or deep third), tumour size ⩾40 mm and presence of vasoinvasion). Human tissue samples were used according to the guidelines of the Ethical Committee of the Leiden University Medical Centre.

Preparation of *IL-23p19*, *IL-12p35* and *IL-12p40* probes
-----------------------------------------------------------

RNA was isolated from frozen human spleen using TRIzol (Invitrogen, Breda, The Netherlands) and first-strand cDNA was synthesised with oligoDT primers and Reverse Transcriptase AMV (both from Roche Diagnostics GmbH, Mannheim, Germany), both according to manufacturer\'s instructions. Oligonucleotide primers for *IL-23-p19*, *IL-12p35* and *IL-12p40* were chosen on the basis of known sequences (see [Table 2](#tbl2){ref-type="table"}), and cDNA encoding for the different cytokines was amplified. A pGEM-3Zf(+) Vector (Promega, Madison, WI, USA) was linearised with *Sma*I and the PCR products were cloned into the vector. After transferring the vector to E. coli strain Top 10 (Invitrogen Corp., San Diego, CA, USA), the plasmids were isolated by using the QIAfilter Maxi KITS protocol (QIAGEN GmbH, Hilden, Germany). The sequence of the PCR product was confirmed by DNA sequencing. Plasmids were linearised with *Bam*H1 and *Eco*R1 (both from Boehringer, Mannheim, Germany) in case of *IL-12p40*, with *Bam*H1 and *Sac*I in case of *IL-12p35* and with *Sac*II, *Sal*I and *Spe*I (Boehringer) in case of *IL-23p19*, using One-Phor-All Buffer Plus (Amersham Biosciences, Roosendaal, The Netherlands). Both strands were translated in a digoxigenin (DIG)-labelled RNA probe according to manufacturer\'s instructions (Roche Diagnostics GmbH). The concentration of the DIG-labelled sense and antisense RNA probes were determined on a 1% agarose gel stained with ethidium bromide (Sigma, St Louis, MO, USA). Probes were stored at −20 °C until further use.

RNA *in situ* hybridisation
---------------------------

The RNA *in situ* hybridisation (RISH) was performed as previously described ([@bib9]; [@bib8]). In short, 3 *μ*m thick paraffin sections were pre-treated and hybridised with 100 ng ml^−1^ DIG-labelled RNA probe diluted in hybridisation mixture containing NaCl and saline-sodium citrate (SSC; [Table 2](#tbl2){ref-type="table"}). Hybridisation was allowed for 16 h at either 55 °C (*IL-23p19*) or 42 °C (*IL-12p35* and *IL-12p40*) in a humidified chamber. Slides were washed 30 min in 2 × SSC, followed by 45 min in 0.1 × SSC with 20 mℳ β-mercaptoethanol (Merck, Darmstadt, Germany), both used at hybridisation temperature (see [Table 2](#tbl2){ref-type="table"}). Subsequently, the slides were incubated for 30 min with 2 U ml^−1^ ribonuclease (RNase) T1 (Roche Diagnostics GmbH) in 2 × SSC, 1 mℳ EDTA at 37 °C. RNA hybrids were detected using, subsequently, mouse anti-DIG (1 : 2000, Sigma-Aldrich Chemie GmbH, Steinham, Germany), rabbit anti-mouse Ig (1 : 50, DAKO, Glostrup, Denmark) and mouse alkaline phosphatase anti-alkaline phosphatase (APAAP, DAKO; [@bib11]).

Immunohistochemistry
--------------------

Serial sections, 3-*μ*m thick, of formalin-fixed and paraffin-embedded tissue were mounted on aminopropylethoxysilane-coated slides. Sections were deparaffinised, rehydrated and treated with 0.3% H~2~O~2~ in methanol for 20 min to block endogenous peroxidase activity.

Antigen retrieval was performed (0.01 ℳ citrate, pH 6.0) and sections were rinsed in phosphate-buffered saline (PBS). Subsequently, sections were stained overnight using either a 1 : 100 dilution of an affinity-purified polyclonal goat anti-human IL-1*β* antibody (AF-201-NA; R&D Systems, Minneapolis, MN, USA) or a 1 : 300 dilution of anti-human polyclonal rabbit anti-IL-6 antibody (Abcam, Cambridge, UK). For anti-IL-1, the slides were incubated with a goat HRP-polymer kit (Biocare Medical, Concord, CA, USA) according to the manufacturer\'s instructions. For anti-IL-6, the slides were incubated with a biotinylated swine anti-rabbit antibody (1 : 200; DAKO) and subsequently incubated with a biotinylated horseradish peroxidase -- streptavidin complex (1 : 100, DAKO), respectively. Immune complexes were visualised with diaminobenzidine as previously described ([@bib8]).

(Semi-)quantitative evaluation of RISH and immunohistochemistry
---------------------------------------------------------------

RISH was scored as previously described ([@bib22]). Intensity was scored as none (0), mild (1), moderate (2) or intense (3) at low magnification ( × 100). Furthermore, the percentage of positive tumour cells was determined and divided in 6 groups: 0% (0, absent), 1--5% (1, sporadic), 6--25% (2, local), 26--50% (3, occasional), 51--75% (4, majority) and 76--100% (5, large majority). The sum of both the percentage and the staining intensity of the positive cells resulted in an overall score (0 or 2 to 8). The scores were combined into three groups: category 0 (score 0, no expression), category 1 (scores 2, 3, 4 and 5, low expression) and category 2 (scores 6, 7 and 8, high expression). mRNA expression was scored by two independent researchers without knowing the identity and clinical outcome of the patients. The IL-1-positive cells and IL-6-positive cells were quantified in the tumour by counting the number of stained cells per six, randomly selected, high-power field of view (HPF, × 400).

Statistical analysis
--------------------

Data from immunohistochemistry as well as RISH are given as the mean±s.d. Statistical analysis was done using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Data were processed by using the *χ*^2^-test. Kaplan--Meier survival curves were generated to assess differences in disease-free period (defined as the observation time in months from surgery to relapse of the disease (disease-free survival)) or cumulative disease-specific survival (defined as time in months from surgery to death due to cervical cancer). A Cox regression was used for multivariate survival analysis. A value of *P*\<0.05 was considered statistically significant.

Results
=======

Patients
--------

Of the group of 90 patients, 68 patients were diagnosed as FIGO stage IB and 21 patients as FIGO stage IIA, and all underwent radical hysterectomy combined with pelvic lymph adenectomy ([Table 1](#tbl1){ref-type="table"}). Forty-seven patients received post-operative radiotherapy because of either tumour-positive lymph nodes or meeting the terms of the Sedlis criteria ([@bib25]; a combination of two of the following unfavourable prognostic parameters: depth of infiltration⩾15 mm, tumour size⩾40 mm and presence of vasoinvasion). Twenty-five patients suffered recurrent disease. At the end of the study, 70 patients were alive, 7 suffered from a recurrence and 18 patients had died of disease.

Expression of *IL-23p19*, *IL-12p35* and *IL-12p40* in cervical cancer
----------------------------------------------------------------------

As IL-12p40 is both a subunit of IL-12 and IL-23, we have determined the expression of *IL-23p19.* Both *IL-23p19* and *IL-12p40* were expressed by cervical tumour cells ([Figure 1A and C](#fig1){ref-type="fig"}). The expression of *IL-12p40* was stronger than the expression of *IL-23p19. IL-23p19* was expressed in 63% of the samples (*n*=54), *IL-12p40* was expressed in 54% of the samples (*n*=90) and *IL-12p35* was expressed in 84% of the samples (*n*=90; [Table 3](#tbl3){ref-type="table"}). All samples that expressed either *IL-23p19* or *IL-12p40* also expressed *IL-12p35 mRNA*. In contrast, 13 out of 44 samples that expressed *IL-12p40* did not express *IL-23p19.*

A positive correlation between *IL-23p19* and *IL-12p40* was found (*n*=54, *r*^2^=0.117, *P*=0.011; data not shown). No statistically significant correlation between *IL-23p19* and *IL-12p35* was found (*n*=54, *r*^2^=0.061, *P*=0.072; data not shown).

Association between *IL-23p19*, *IL-12p35* and *IL-12p40*, and disease-specific survival in cervical cancer
-----------------------------------------------------------------------------------------------------------

To investigate the relationship between the expression of *IL-23p19*, *IL-12p35* and *IL-12p40*, and disease-specific survival, Kaplan--Meier plots were created. A log-rank test was used to determine statistical differences in disease-specific survival. As the absence of *IL-12p40* will result in neither IL-12 nor IL-23, we first confirmed that expression of *IL-12p40* was associated with poor disease-specific survival ([Figure 2A](#fig2){ref-type="fig"}; *n*=48, log-rank test 5.753, *P=*0.017) in this cohort. The expression of *IL-12p35* ([Figure 2B](#fig2){ref-type="fig"}; *n*=74, log-rank test 0.2019, *P=*0.653) and the expression of *IL-23p19* ([Figure 2C](#fig2){ref-type="fig"}; *n*=33, log-rank test 1.930, *P=*0.165) were both not significantly associated with disease-specific survival. The expression of *IL-23p19*, *IL-12p35* or *IL-12p40* showed no significant difference in disease-free survival (data not shown).

Presence of IL-6-positive cells and association with disease-specific survival in cervical cancer
-------------------------------------------------------------------------------------------------

The presence of *IL-23p19* suggests that IL-23 may sustain a Th17-positive cell population in cervical cancer. As differentiation towards the IL-17/IL-23 pathway is thought to occur in the presence of IL-1 and IL-6 in humans ([@bib1]), we have determined the presence of IL-1 and IL-6-positive cells, using immunohistochemistry. Interleukin-1 was predominantly expressed by cells in the stromal compartment. Occasionally, tumour cells also showed weak IL-1 expression. No statistically significant association between low or high number of IL-1-expressing cells and disease-specific survival was observed ([Figure 3A](#fig3){ref-type="fig"}). Interleukin-6 was expressed by both cells in the epithelial (tumour cell) compartment and cells in the stromal compartment ([Figure 1E](#fig1){ref-type="fig"}). No significant association was observed between low or high IL-6 expression of cells in the epithelial compartment and disease-specific survival ([Figure 1F](#fig1){ref-type="fig"}). Subsequently, we quantified the number of IL-6-positive cells in the stroma. The presence of a high number of IL-6 stromal positive cells (median 17 IL-6-positive cells/HPF) significantly associated with disease-specific survival ([Figure 3B](#fig3){ref-type="fig"}; *n*=83, log-rank test 12.57, *P\<*0.001). No statistical significant difference was observed for disease-free survival (data not shown). We also determined whether disease-specific survival was associated with the presence of both a high number of IL-6-positive stromal cells and low *IL-12p40*. In this latter case, an even stronger decrease in disease-specific survival was observed ([Figure 3C](#fig3){ref-type="fig"}; *n*=47, log-rank test 20.38, *P\<*0.001).

Association between low *IL-12p40* expression, high number of IL-6-positive stromal cells and clinicopathological parameters
----------------------------------------------------------------------------------------------------------------------------

To determine the relevance of our findings, we associated our immunological findings with clinicopathological parameters. First, a univariate Cox analysis was performed, using the clinical parameters, Sedlis criteria (two out of three of the following criteria positive: tumour size⩾40 mm, vasoinvasion and deep stromal invasion), lymph node metastasis and parametrial involvement and the immunological parameters, low *IL-12p40* expression, high number of IL-6-positive cells and high number of IL-6-positive cells, plus low *IL-12p40* expression. In the univariate Cox analyses, all the included parameters showed a significantly increased hazard ratio (HR; [Table 4](#tbl4){ref-type="table"}). Subsequently, a multivariate Cox analysis with the three clinicopathological parameters and each of the significantly immunological parameters was performed. In this case, two of the three immunological parameters, high number of IL-6-positive stromal cells (*P*=0.009; HR, 7.447) and high number of IL-6-positive stromal cells and low *IL-12p40* expression (*P*=0.007; HR, 20.123) were shown to be independent predictors of poor disease-specific survival.

Discussion
==========

In a previous study, we found an association between low expression of *IL-12p40* and poor disease-specific survival, whereas high expression of *IL-12p40* or lack of expression of *IL-12p40* were associated with a favourable disease-specific survival ([@bib42]). As IL-12p40 combines with both IL-12p35 and IL-23p19, to form IL-12 and IL-23, respectively, in the present study, we have further investigated the role of *IL-12p40* in cervical cancer.

Both *IL-23p19* and *IL-12p35* were expressed in the majority of the samples. Out of the 44 samples that expressed *IL-12p40*, 13 samples did not express *IL-23p19*. As *IL-12p35* expression seems to be ubiquitous in cervical cancer ([@bib42]), the level of *IL-12p40* or *IL-23p19* expression most probably determines whether IL-12, IL-23 or both are expressed. In our study, we observed a trend (*P*=0.061; *n*=54) between *IL-23p19* or *IL-12-p35* expression, whereas in the study of [@bib37] in ovarian cancer (*n*=112) a significant correlation between the expression of *IL-23p19* and *IL-12p35* was found. The discrepancy between our results and the results of [@bib37] may be due to the smaller size of our study group. Very few studies have investigated the association between local expression of IL-12 or IL-23, and prognosis. Using immmunohistochemistry, IL-12 has been associated with improved survival in patients with (advanced) gastric carcinoma ([@bib39]; [@bib20]). In the study of [@bib37], using RT-PCR, both *IL-12p35* and *IL-23-p19* were associated with a superior outcome. In a multivariate analysis, *IL-12p35* was found to be an independent factor for overall survival of ovarian carcinoma. As stated previously, we have observed a statistically significant association between low expression of *IL-12p40* and poor disease-specific survival in cervical carcinoma ([@bib42]). In the present study and our previous study ([@bib42]), we did not find a significant association between either *IL-23p19* or *IL-12p35* expression and disease-specific survival. As *IL-23p19* and *IL-12p35* are both expressed, it is important to determine which cytokine, IL-23 or IL-12, has a dominant effect on the tumour microenvironment.

The molecular interaction between IL-23p19 and IL-12p40 has been studied by [@bib3]. These authors reported that the interface region of IL-23p19 and IL-12p35 on IL-12p40 overlap. Because of different interresidue interactions of IL-12p35 and IL-23p19 with IL-12p40, these molecules interact with a different affinity with IL-12p40. Therefore, the availability of IL-12p40 in combination with the affinity for IL-12p35 and IL-23-p19 may result in skewing of the IL-12/IL-23 response. This is supported by experiments performed by [@bib43]. These authors showed that in an experimental animal model, polymorphic variants of IL-12p40 can skew IL-12/IL-23 synthesis ([@bib43]). Thus, both differences in protein interactions between IL-23p19 and IL-12p35 on the one hand and IL-12p40 on the other hand, and genetic polymorphisms in the protein chains, such as IL-12p40, contribute to the amounts of IL-12 and IL-23 formed. Our results support a previously suggested immunosuppressive role for IL-23 ([@bib16]). This is further supported by a study in ovarian carcinoma where genetic differences in the IL-23 receptor have been reported to influence prognosis ([@bib40]).

In contrast, it has also been shown that overexpression of IL-23 reduces tumour growth and metastasis formation, and that IL-23 is able to elicit a strong cytotoxic T-cell memory response ([@bib17]; [@bib26]), underscoring our view that the level of expression of the different cytokines and chemokines has an import role in the final outcome.

Our data suggest that in the presence of a limited amount of *IL-12p40* the biological effect of IL-23 dominates, whereas in the presence of a high amount of *IL-12p40* the biological effect of IL-12 prevails. As IL-12 polarises the immune response towards an antiviral response, ([@bib31]) the favourable cumulative overall survival of patients with a high IL-12-positive cell density ([@bib39]; [@bib20]) and high expression level of *IL-12p35* ([@bib37]) and *IL-12p40* ([@bib42]) can be explained by the capacity of this cytokine to increase the lytic activity and the production of interferon-*γ* of natural killer cells and cytotoxic T lymphocytes ([@bib31]). Interestingly, we previously observed an association between high expression of *IL-12p40* and high expression of *TGF-β* (*P*=0.024; [@bib42]), suggesting that the tumour cells are selected to counter act the effect of IL-12 or skew the response to the IL-17/IL-23 pathway.

In humans, in addition to IL-1, IL-6 and TGF-*β* have been implicated to have a role in the IL-17/IL-23 pathway ([@bib33]; [@bib1]). Previously, we have shown that it is likely that activated TGF-*β* is present in the tumour microenvironment, as PAI-1, a target gene of TGF-β, is expressed and expression of PAI-1 is associated with survival ([@bib13]). Furthermore, both the integrin av*β*6 and active matrix metalloproteinase-2, known to activate TGF-*β*, are associated with poor disease-specific survival ([@bib27]; [@bib12]). Even though the role of TGF-*β* in inducing Th17 in humans has been questioned, TGF-*β* may suppress Th1 and Th2 development, thus favoring Th17 development ([@bib23]; [@bib7]).

In our study, low or high numbers of IL-1-positive cells were not associated with disease-specific survival. The presence of a high number of IL-6-expressing stromal cells was significantly associated with poor disease-specific survival (*P*\<0.001). Previously, IL-6 has been implicated as an autocrine or paracrine growth factor for cervical cancer ([@bib30]; [@bib4]). Interleukin-6 has been shown to induce VEGF transcription via the STAT3 signalling pathway, thus promoting an angiogenic switch ([@bib36]). Indeed, blockade of the IL-6 receptor on cervical cancer cell lines was shown to interfere with cell survival signals and blocked the expression of VEGF ([@bib29]).

As HPV vaccines will become available for the treatment of metastasised cervical carcinoma, the local cytokine/chemokine profile may be important to discriminate patients with a beneficial immune response from non-responding patients.

In conclusion, *IL-12p40* has at least a dual role in cervical carcinoma by associating with both *IL-23p19* and *IL-12p35*. We have shown that low *IL-12p40* expression was significantly associated with poor disease-specific survival (*P*=0.017). Also, a high number of stromal IL-6-producing cells was shown to associate with poor disease-specific survival (*P*\<0.001). The worst disease-specific survival was observed in a subgroup of patients that displayed a high number of stromal IL-6-expressing cells and low *IL-12p40* expression (*P*\<0.001). Furthermore, both a high number of stromal IL-6-expressing cells and a high number of stromal IL-6, plus *IL-12p40* expression, were shown to be independent clinicopathological parameters compared with lymph node metastasis, parametrial involvement and Sedlis score (*P*=0.009 and *P*=0.022, respectively). Our results with IL-6 and *IL-12p40* are in accordance with the hypothesis that the IL-17/IL-23 pathway has a suppressive role in cervical cancer.
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![The expression of *IL-23p19*, *IL-12p40* and IL-6. The expression of *IL-23p19* and *IL-12p40* were determined using RISH, and the expression of IL-6 was determined using immunohistochemistry as described in the Materials and Methods ( × 250 magnification). (**A**) Cervical tumour, *IL-23p19* RISH. Tumour cells stain positive (moderate) for *IL-23p19*; (**B**) negative (sense) control of *IL-23p19* RISH; (**C**) cervical tumour, *IL-12p40* RISH. Tumour cells stain positive (strong) for *IL-12p40*; (**D**) negative (sense) control of *IL-12p40* RISH. (**E**) IL-6 staining of cervical cancer tissue. Both cells in the epithelial compartment (EC) as well as cells in the stroma express IL-6. Arrow indicates positive stromal cells. Detail ( × 400 magnification) of IL-6-positive cells in the stroma; and (**F**) association between cells in the epithelial compartment wit low (IL-6 EC low) and high IL-6 (IL-6 EC high) expression and disease-specific survival. Bars correspond to 50 *μ*m in **A**--**E** and to 10 *μ*m in the inset of **E**. No significant association between low or high IL-6 expression of the epithelial cells with disease-specific survival was observed.](bjc2012488f1){#fig1}

![Association between *IL-12p40* (**A**), *IL-12p35* (**B**) and *IL-23p19* (**C**) expression and disease-specific survival in cervical carcinoma. *IL-23p19*, *IL-12p35* and *IL-12p40* were determined by RISH as described in the Materials and Methods.](bjc2012488f2){#fig2}

![Association between high number of IL-1-positive cells (**A**), high number of IL-6-positive stromal cells (**B**) and *IL-12p40* expression in combination with high number of IL-6- positive stromal cells (**C**) and disease-specific survival. The IL-1 and IL-6 expression were determined by immunohistochemistry as described in Materials and Methods. *IL-12p40* was determined by RISH as described in the Materials and Methods.](bjc2012488f3){#fig3}

###### Summary of clinicopathological features of patients and tumours

  **Patient and tumour characteristics**                  **Outcome**      ***N***[a](#t1-fn3){ref-type="fn"}
  ------------------------------------------------------- ---------------- ------------------------------------
  Age                                                     45 (mean)        90
                                                          29--76 (range)    
  FIGO[b](#t1-fn3){ref-type="fn"} stage                   IB               68
                                                          IIA              21
  Lymph node metastasis                                   No               66
                                                          Yes              22
  Tumour size[b](#t1-fn3){ref-type="fn"}                  \< 40 mm         37
                                                          ⩾ 40 mm          26
  Depth of infiltration[b](#t1-fn3){ref-type="fn"}        \< 15 mm         58
                                                          ⩾ 15 mm          26
  Vascular space involvement[b](#t1-fn3){ref-type="fn"}   No               39
                                                          Yes              47
  Sedlis criteria[c](#t1-fn4){ref-type="fn"}              Positive         28
                                                          Negative         52
  Parametrial invasion[b](#t1-fn3){ref-type="fn"}         No               74
                                                          Yes              14
  HPV status[d](#t1-fn5){ref-type="fn"}                   16, 18           66
                                                          Others           15
  Histology                                               Squamous         58
                                                          Adenosquamous    18
                                                          Adeno            7
                                                          Others           6

Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; HPV=human papillomavirus.

N is the number of patients/cervical carcinomas.

The number of reported cases is affected by incidental missing cases.

Sedlis criteria ([@bib25]): a combination of two of the following unfavourable prognostic parameters: depth of infiltration⩾15 mm (deep stromal invasion; middle or deep third), tumour size ⩾40 mm and presence of vasoinvasion.

Only data for cervical carcinoma samples with a determined HPV type were included. Other subtypes included HPV31 (*n*=2), HPV33 (*n*=6), HPV35 (*n*=1), HPV45 (*n*=3), HPV58 (*n*=1), HPV59 (*n*=2) and HPV68 (*n*=1).

###### RNA probes used and RNA-*in situ* hybridisation conditions

  **Target**   **Primer**   **Sequence (5′--3′)**    **Product (bp)**    **Accession number**  **Position**   **Hybr. temp. (°C)**
  ------------ ------------ ------------------------ ------------------ ---------------------- -------------- ----------------------
  *IL-23p19*   Forward      AGAGCCAGCCAGATTTGAGA     487                     NM_016584.2       134--620       55
               Reverse      GCAGATTCCAAGCCTCAGTC                                                               
  *IL-12p35*   Forward      TGCTCCAGAAGGCCAGACAAAC   465                      XM_003121        320--784       42
               Reverse      CCCGAATTCTGAAAGCATGAAG                                                             
  *IL-12p40*   Forward      GGACCAGAGCAGTGAGGTCTT    373                      XM_004011        189--561       42
               Reverse      CTCCTTGTTGTCCCCTCTGA                                                               

Abbreviation: Hybr. temp.=hybridisation temperature.

###### Correlation between *IL-23p19*, *IL-12p35* and *IL-12p40* expression in cervical carcinoma.

                                                    ***IL-12p35***                       
  ------------ ------------------------------------ ---------------- --------- --------- -------------
  *IL-12p40*   Absent                               14               21        6         41 (46)
               Low                                  0                14        14        28 (31)
               High                                 0                3         18        21 (23)
  Total        *n* (%)[a](#t3-fn1){ref-type="fn"}   14 (16)          38 (42)   38 (42)   90 (100)
  *P*-value                                                                              **\<0.001**
                                                    ***IL-23p19***                       
  *IL-12p40*   Absent                               7                1         2         10 (19)
               Low                                  8                5         11        24 (44)
               High                                 5                4         11        20 (37)
  Total        *n* (%)[a](#t3-fn1){ref-type="fn"}   20 (37)          10 (19)   24 (44)   54 (100)
  *P*-value                                                                              0.188
                                                    ***IL-23p19***                       
  *IL-12p35*   Absent                               1                0         0         1 (2)
               Low                                  8                5         8         21 (39)
               High                                 11               5         16        32 (59)
  Total        *n* (%)[a](#t3-fn1){ref-type="fn"}   20 (37)          10 (19)   24 (44)   54 (100)
  *P*-value                                                                              0.619

*n*=number of tumours. The scores were combined into three groups: absent expression, low expression and high expression as described in Materials and Methods. Statistically significant *P*--value is given in bold.

###### Cox regression of clinicopathological variables and *IL-12p40* and the number of IL-6-positive cells in cervical carcinoma

  **Univariate**                              **Hazard ratio**   **95% CI**       ***P*****-value**
  ------------------------------------------- ------------------ ---------------- -------------------
  Sedlis positive                             4.354              1.608--11.789    **0.004**
  Lymph node metastasis                       3.266              1.286--8.296     **0.013**
  Parametrial involvement                     3.645              1.411--9.411     **0.008**
  Low *IL-12p40*                              5.231              1.156--23.661    **0.032**
  High number of IL-6 cells                   8.975              2.063--39.051    **0.003**
  Low number of IL-6 cells                    Reference                            
  High number of IL-6 cells/low *IL-12p40*    21.832             2.805--169.915   **0.003**
                                                                                   
  *Multivariate*                                                                  
   Sedlis positive                            3.848              1.270--11.663    **0.017**
   Lymph node metastasis                      1.333              0.439--4.052     0.612
   Parametrial involvement                    1.526              0.542--4.444     0.438
   High number of IL-6 cells                  7.447              1.659--33.432    **0.009**
                                                                                   
  *Multivariate*                                                                  
   Sedlis positive                            0.706              0.150--3.310     0.659
   Lymph node metastasis                      2.887              0.836--9.965     0.094
   Parametrial involvement                    1.168              0.283--4.822     0.830
   Low number of IL-6 cells                   Reference                            
   High number of IL-6 cells/low *IL-12p40*   20.123             2.248--180.147   **0.007**

Abbreviation: CI=confidence interval.

Shown are the log-rank test and *P-*value of compared expression levels. Statistically significant *P-*values are given in bold.
